Precigen's PAPZIMEOS Therapy Gains Momentum and Acceptance for RRP Treatment at J.P. Morgan Healthcare Conference

Precigen Showcases PAPZIMEOS at J.P. Morgan Healthcare Conference

Precigen, Inc. recently made significant waves in the biopharmaceutical community as they showcased their pioneering therapy, PAPZIMEOS, at the 44th Annual J.P. Morgan Healthcare Conference. This therapy is notably the first and only one to receive FDA approval specifically for treating recurrent respiratory papillomatosis (RRP) in adults, marking a turning point in how this rare condition is addressed. The conference, which takes place from January 15, 2026, underscores the urgency and importance of innovative treatments in the healthcare landscape.

Rapid Commercialization Progress

Since receiving FDA approval back in August 2025, Precigen has transitioned into a commercial stage company, this marks a critical development in its mission to bring advanced healthcare solutions to patients. PAPZIMEOS is experiencing a rapid rollout across the nation, with numerous patients actively being treated. As of January 2026, over 200 patients have enrolled in the PAPZIMEOS patient hub, reflecting a doubling of registrations since November. Such growth emphasizes the high demand from both patients and healthcare providers.

Precigen's President and CEO, Dr. Helen Sabzevari, highlighted the enthusiastic response from physicians nationwide who are keen to introduce this therapy to their patients. The enthusiasm is supported by compelling safety and efficacy data, promising a lasting impact for those living with RRP. The enthusiasm surrounding this therapy indicates a positive shift in the treatment paradigm for RRP, a condition traditionally managed with repeated surgeries that do not target the underlying causes.

Expanding Accessibility and Coverage

A crucial aspect of PAPZIMEOS's commercial strategy is the expanding accessibility that has been made available through various private health plans. Currently, approximately 170 million lives across the United States are covered under these private health plans, in addition to Medicare and Medicaid, enabling more patients to access this groundbreaking therapy. This push for accessibility is essential for making PAPZIMEOS not only a treatment option but the standard of care for RRP.

The European Medicines Agency (EMA) recently validated the Marketing Authorization Application for PAPZIMEOS, bringing the therapy one step closer to being available for patients in Europe. This validation is a testament to Precigen's commitment to global expansion and the urgent need for effective treatments in the international market.

The Clinical Importance of PAPZIMEOS

RRP is a chronic, debilitating condition caused predominantly by HPV infections, leading to recurrent growths in the respiratory tract that can severely impact patients' quality of life. The implications of RRP are profound, with significant burdens on patients, from health complications to emotional struggles and financial instability. Traditional management often requires multiple surgeries that can result in irreversible damage over time.

PAPZIMEOS offers a new hope for these patients, as it is designed to tackle the root cause of RRP. This non-replicating adenoviral vector-based immunotherapy aims to elicit an immune response against HPV 6 and 11 proteins, thus providing a groundbreaking approach to managing this chronic condition.

The company's internal analysis estimates about 27,000 adults in the US are affected by RRP, highlighting the pressing need for effective treatment options like PAPZIMEOS. Precigen is dedicated to harnessing innovative science to combat such unmet medical needs, which align with their broader mission of providing precision therapies for complex and challenging health conditions.

Conclusion

As Precigen prepares for a commercial launch of PAPZIMEOS, their presentation at the J.P. Morgan Healthcare Conference is more than just an opportunity for networking; it represents a critical milestone in their ongoing mission to change the narrative around RRP treatment. By emphasizing rapid commercialization, broad market acceptance, and continued dedication to innovation, Precigen is solidifying its role as a leader in the advancement of therapeutic options for patients in need.

With PAPZIMEOS, the company is promising not just a treatment, but a potential new standard of care for adults battling RRP. The journey ahead might still be challenging, but the momentum is firmly in place as Precigen steps into a future of possibilities for patients suffering from this debilitating condition.